Malta - English - Medicines Authority

clonmel healthcare limited waterford road, clonmel, co. tipperary e91 d768, ireland - ibandronic acid - film-coated tablet - ibandronic acid 150 mg - drugs for treatment of bone diseases

Malta - English - Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - ibandronic acid - film-coated tablet - ibandronic acid 150 mg - drugs for treatment of bone diseases

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arrow generics ltd - ibandronic sodium monohydrate - tablet - 150mg

Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - ibandronate sodium monohydrate - concentrate for solution for infusion - 6 milligram(s) - bisphosphonates; ibandronic acid

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - ibandronic acid, monosodium salt, monohydrate eqv. to ibandronic acid - injection - 1mg/ml - ibandronic acid, monosodium salt, monohydrate eqv. to ibandronic acid 1mg/ml

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. - ibandronate sodium (unii: j12u072ql0) (ibandronic acid - unii:umd7g2653w) - ibandronic acid 3 mg in 3 ml - ibandronate sodium injection is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, ibandronate increases bone mineral density (bmd) and reduces the incidence of vertebral fractures [see clinical studies(14)]. the safety and effectiveness of ibandronate for the treatment of osteoporosis are based on clinical data of one year duration. the optimal duration of use has not been determined. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. ibandronate is contraindicated in patients with the following conditions: - hypocalcemia [see warnings and precautions (5.1)] - known hypersensitivity to ibandronate sodium injection or to any of its excipients. cases of anaphylaxis, including fatal event

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

roche diagnostics gmbh - ibandronic acid - solution for i/v injection - 1mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva - ibandronic sodium monohydrate - tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution - ibandronic sodium monohydrate - tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - ibandronic sodium monohydrate - tablet - 50mg